Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma.
Yusuke KawamuraNorio AkutaJunichi ShindohMasaru MatsumuraSatoshi OkuboLicht TominagaShunichiro FujiyamaTetsuya HosakaSatoshi SaitohHitomi SezakiFumitaka SuzukiYoshiyuki SuzukiKenji IkedaYasuji AraseMasaji HashimotoTakuyo KozukaHiromitsu KumadaPublished in: Clinical journal of gastroenterology (2022)
Curative-intent subsequent treatment is more useful for HCC patients with better liver function (mALBI grade 1 and 2a) and intrahepatic target nodules who have received lenvatini b-based treatment.
Keyphrases